Under the agreement the two companies will carry out collaborative research to jointly develop biosimilars for the world market. Kissei is expected to make milestone payments to Alteogen for some of the research.

Kissei will have exclusive rights to market the biosimilars in Japan, with both companies having joint sales rights in other regions of the world.

Alteogen’s management team has ‘extensive experience for the research and development of biosimilars’ and the company has reportedly already used its ‘expertise in CHO cell technology’ to jointly develop biosimilar monoclonal antibody products with ‘internationally recognized pharmaceutical companies’. Kissei, on the other hand, expects the collaboration with Alteogen to further strengthen the company’s biopharmaceutical business.

Editor’s comment

Readers interested to learn more about biosimilars regulations in Japan and other countries/regions are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Comparison of biosimilars guidelines 

If you are interested in contributing a research article in a similar area to the GaBI Journal, please send us your submission here.

Related article

Japanese firms developing biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.